Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FE 999322 and FE 999324 in Mild to Moderate Ulcerative Colitis
NCT06260267Phase 1Withdrawn
- Sponsor
- Ferring Pharmaceuticals
- Start
- Mar 2024
- Primary completion
- Jan 2026
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of RBX2660 and FE 999324 in ulcerative colitis (UC) (4 arms), sponsored by Ferring Pharmaceuticals. Primary endpoint: Treatment-Emergent Adverse Events at 52 weeks. Planned start Mar 2024; status: withdrawn.
02
Drugs
RBX2660FE 999324
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT06260267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06260267.